Human papillomavirus type 18 L1 capsid protein antigen

DB10302ApprovedInvestigationalVaccinesInactivated Human Papillomavirus Vaccine

Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is... It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

First approval
Canada, 2006 · United States, 2006 · European Union, 2020
Also known as
L1 protein, Human papillomavirus type 18 Vaccine · Recombinant human papillomavirus type 18 L1 protein
Brand names
  • Cervarix
  • Gardasil
  • Gardasil 9

Resolves to

Compound
UNIIJ2D279PEM5
Clinical / RWD
RxNorm798266

What you can answer from here — as of April 02, 2025

187Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
82Marketed productsAcross 9 countries and 12 labellers
Sign in

Which other approved drugs treat the same conditions as Human papillomavirus type 18 L1 capsid protein antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In